Dandekar Atul
Dandekar Atul, CSBO, reported a transaction classified as exercise at Maze Therapeutics, Inc. involving 7500.000000 shares for an estimated $0.00. Reported holdings after the transaction were 14143.000000 shares. The stored filing text includes a detected 10b5-1 reference.
- Trade date
- Aug 28, 2026
- Filing date
- Aug 31, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
MAZE price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0002050167-26-000023 Stock Option (Right to Buy)
- Transaction date
- Aug 28, 2026 Filed Aug 31, 2026, 10:32 PM · 3d delay
- Shares
- 7,500 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 14,143 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-20 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a meaningfully negative filing-only score. It is likely less useful as a positive insider-activity signal.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - tenb5_1_detected-10 points
is_10b5_1 = true
Stored filing content includes detected 10b5-1 language.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
CSBO
- F1
This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.31 to $28.01 per share, inclusive. The reporting person undertake…
- F3
The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
0 other transactions
0 recent txs